IL-10 is prognostic and may be associated with JAK-1 activation. (A) Patients with non-HIV–associated PCNSL and SCNSL with elevated concentration of IL-10 in CSF at diagnosis (N = 18) (above 45 pg/mL, the median concentration among all CNS lymphoma patients) exhibited significantly shorter TTP compared with patients with low CSF IL-10 (N = 21). P = .05 (hazard ratio = 2.33). The median TTP (as well as PFS) of PCNSL and SCNSL patients with low CSF IL-10 at diagnosis is 82 months vs 10 months for patients with elevated CSF IL-10. The median OS of CNS lymphoma patients with low CSF IL-10 at diagnosis was 84 months, whereas the median OS of patients with elevated CSF IL-10 at diagnosis has not been reached. P < .057 (hazard ratio = 3.6) (not shown). All patients were treated with a high-dose methotrexate-based induction regimen without whole brain irradiation consolidation. Patients with stage IV DLBCL with CNS involvement received cyclophosphamide, vincristine, adriamycin, and prednisone instead of temozolomide, as described.27 Germinal center B cells in reactive tonsils (B) exhibited weak to absent immunoreactivity for JAK-1 activation (phosphorylation of JAK-1 at tyrosine 1022), whereas strong intratumoral JAK-1 activation (>30% lymphoma cells) was detected in 70% of diagnostic specimens of PCNSL (N = 30) (C) (×1000).
